Skip to main content

Clinical Trials Using Thymidylate Synthase Inhibitor

Review the clinical trials studying thymidylate synthase inhibitor on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 261

Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Status: Active
Location: 980 locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Status: Active
Location: 1051 locations
mFOLFIRINOX versus mFOLFOX with or without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Status: Active
Location: 686 locations
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 455 locations
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Status: Active
Location: 448 locations
Comparing Impact of Treatment Before or After Surgery in Patients with Stage II-IIIB Resectable Non-small Cell Lung Cancer
Status: Active
Location: 350 locations
Chemotherapy Combined with Immunotherapy versus Immunotherapy alone for Older Adults with Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Status: Active
Location: 306 locations
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 257 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Status: Active
Location: 202 locations
Testing Chemotherapy versus Chemotherapy plus Radiotherapy Prior to Limited Surgery for Early Rectal Cancer
Status: Active
Location: 97 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Status: Active
Location: 99 locations
Studying Chemotherapy with or without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Status: Active
Location: 77 locations
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Status: Active
Location: 76 locations
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Status: Active
Location: 56 locations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Location: 47 locations
Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma
Status: Active
Location: 37 locations
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Status: Active
Location: 36 locations
Testing the Addition of Paclitaxel Administered into the Abdominal Cavity Combined with Chemotherapy for Patients with Gastric Cancer Spread to the Abdominal Cavity, STOPGAP II Trial
Status: Active
Location: 33 locations
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) during Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Status: Active
Location: 32 locations
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Status: Active
Location: 36 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 25 locations
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Status: Active
Location: 20 locations
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Status: Active
Location: 20 locations
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Status: Active
Location: 18 locations
Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers
Status: Active
Location: 16 locations